全部树

Cost of living data for global residentsNEW

China high-tech enterprise patent statisticsNEW

Statistics on entry and exit information of Chinese partnershipsNEW

Patents and citation data of Little Giant and individual champion companiesNEW

Small giant and single champion enterprise design patent details table

Digital economy patent application and authorization dataNEW

Tax investigation of corporate patents and citation dataNEW

Patent and citation data of Chinese industrial enterprisesNEW

Patent and citation data of A-share listed companiesNEW

Patent details of A-share listed companies
A-share listed companies' design patent application details table
Details of Design Patents Authorized by A-share Listed Companies

Statistics on the entry and exit of Chinese industrial and commercial enterprisesNEW

Basic information data of manufacturing industrial and commercial registered enterprisesNEW

China foreign trade index data

China university patent statisticsNEW

Green patents and citation data of Chinese industrial enterprisesNEW

Details of Green Patents of Chinese Industrial Enterprises

Green patents and citation data of A-share listed companies

A-share listed companies green patent details table

   Since the outbreak of the COVID-19 pandemic, practical experience from epidemic control efforts across China has demonstrated that nucleic acid testing plays a crucial role in early detection of positive cases. As such, it has been vigorously implemented as a fundamental measure in regular epidemic prevention and control. Currently, numerous specialized nucleic acid testing institutions have been established nationwide. According to regulations set by the National Health Commission, medical and health institutions providing nucleic acid testing services in China are primarily categorized into three types: first, medical institutions such as hospitals and maternal and child health hospitals; second, disease control agencies, including Centers for Disease Control and Prevention (CDCs) at national, provincial, municipal, and county levels, which also offer nucleic acid testing services; and third, medical testing laboratories, which fall under the category of medical institutions and are commonly referred to as "third-party testing agencies."

   In late 2022, health administrative departments in cities such as Lanzhou, Beijing, Hefei, Shijiazhuang, Xuchang, and Inner Mongolia discovered that some nucleic acid testing institutions had engaged in serious illegal activities, including issuing false test reports. Certain nucleic acid testing companies, acting as third-party testing agencies, have attracted widespread public attention.

   Against this backdrop, CnOpenData has collected comprehensive industrial and commercial information on all nucleic acid testing institutions, including basic industrial and commercial information, shareholder details, shareholders' external investment data, and records of industrial and commercial changes. This dataset aims to support relevant research endeavors.


Time Range

As of July 31, 2023 (no further updates)


Field Display


Sample Data

Given the extensive number of tables in this dataset, only partial tables are displayed on this page. For detailed data content, please refer to the subtables listed on the left.

Basic Industrial and Commercial Data of Nucleic Acid Testing Institutions

Registered Capital Contribution Data of Nucleic Acid Testing Institutions

Basic Shareholder Data of Nucleic Acid Testing Institutions

External Investment Data of Shareholders in Nucleic Acid Testing Institutions

External Investment Data of Nucleic Acid Testing Institutions


Data Update Frequency

No updates